AR080256A1 - Formulaciones farmaceuticas solidas de ramipril y besilato de amlodipino y su preparacion - Google Patents

Formulaciones farmaceuticas solidas de ramipril y besilato de amlodipino y su preparacion

Info

Publication number
AR080256A1
AR080256A1 ARP110100551A ARP110100551A AR080256A1 AR 080256 A1 AR080256 A1 AR 080256A1 AR P110100551 A ARP110100551 A AR P110100551A AR P110100551 A ARP110100551 A AR P110100551A AR 080256 A1 AR080256 A1 AR 080256A1
Authority
AR
Argentina
Prior art keywords
ramipril
besylate
solid pharmaceutical
amlodipino
preparation
Prior art date
Application number
ARP110100551A
Other languages
English (en)
Original Assignee
Sanofi Aventis Deutschland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42786564&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR080256(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanofi Aventis Deutschland filed Critical Sanofi Aventis Deutschland
Publication of AR080256A1 publication Critical patent/AR080256A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J3/00—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
    • A61J3/10—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms into the form of compressed tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
    • B65B—MACHINES, APPARATUS OR DEVICES FOR, OR METHODS OF, PACKAGING ARTICLES OR MATERIALS; UNPACKING
    • B65B3/00—Packaging plastic material, semiliquids, liquids or mixed solids and liquids, in individual containers or receptacles, e.g. bags, sacks, boxes, cartons, cans, or jars
    • B65B3/04—Methods of, or means for, filling the material into the containers or receptacles
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
    • B65D—CONTAINERS FOR STORAGE OR TRANSPORT OF ARTICLES OR MATERIALS, e.g. BAGS, BARRELS, BOTTLES, BOXES, CANS, CARTONS, CRATES, DRUMS, JARS, TANKS, HOPPERS, FORWARDING CONTAINERS; ACCESSORIES, CLOSURES, OR FITTINGS THEREFOR; PACKAGING ELEMENTS; PACKAGES
    • B65D11/00—Containers having bodies formed by interconnecting or uniting two or more rigid, or substantially rigid, components made wholly or mainly of plastics material
    • B65D11/20—Details of walls made of plastics material

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mechanical Engineering (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Reivindicacion 1: Una composicion farmacéutica solida oral de dosis fija que comprende Ramipril, besilato de amlodipino y excipientes farmacéuticamente aceptables, en donde el ramipril en forma de gránulos recubiertos está embebido en una matriz extragranular que comprende besilato de amlodipino. Reivindicacion 9: La composicion solida segun una cualquiera de las reivindicaciones 1 a 8 en forma de un comprimido en donde el peso total del comprimido está entre 80mg y 100mg, preferiblemente 100mg.
ARP110100551A 2010-02-24 2011-02-23 Formulaciones farmaceuticas solidas de ramipril y besilato de amlodipino y su preparacion AR080256A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN417DE2010 2010-02-24
PCT/IB2010/051616 WO2011104588A2 (en) 2010-02-24 2010-04-14 Solid pharmaceutical formulations of ramipril and amlodipine besylate, and their preparation

Publications (1)

Publication Number Publication Date
AR080256A1 true AR080256A1 (es) 2012-03-21

Family

ID=42786564

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP110100551A AR080256A1 (es) 2010-02-24 2011-02-23 Formulaciones farmaceuticas solidas de ramipril y besilato de amlodipino y su preparacion

Country Status (28)

Country Link
US (1) US20130146496A1 (es)
EP (1) EP2538924B1 (es)
JP (1) JP5719385B2 (es)
KR (1) KR20120130761A (es)
CN (1) CN102781430B (es)
AR (1) AR080256A1 (es)
AU (1) AU2010346977A1 (es)
BR (1) BR112012021203A2 (es)
CA (1) CA2790817A1 (es)
CL (1) CL2012002341A1 (es)
CR (1) CR20120432A (es)
EA (1) EA201290817A1 (es)
EC (1) ECSP12012121A (es)
ES (1) ES2483154T3 (es)
GT (1) GT201200248A (es)
MA (1) MA34130B1 (es)
MX (1) MX2012009689A (es)
NI (1) NI201200136A (es)
PE (1) PE20130004A1 (es)
PL (1) PL2538924T3 (es)
SG (1) SG183449A1 (es)
SI (1) SI2538924T1 (es)
TN (1) TN2012000363A1 (es)
TW (1) TW201138767A (es)
UA (1) UA105285C2 (es)
UY (1) UY33243A (es)
WO (1) WO2011104588A2 (es)
ZA (1) ZA201205559B (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2814465B1 (en) * 2012-02-17 2019-07-03 Egis Gyógyszergyár Zrt. Pharmaceutical formulation having improved stability
PL227900B1 (pl) * 2012-11-15 2018-01-31 Adamed Spolka Z Ograniczona Odpowiedzialnoscia Kompozycja farmaceutyczna zawierająca inhibitor ACE i bloker kanałów wapniowych, sposób jej wytwarzania i jednostka dawkowania zawierająca tę kompozycję
CN104546773B (zh) * 2015-01-30 2018-12-11 华润赛科药业有限责任公司 一种高稳定性苯磺酸氨氯地平片及其制备方法
WO2016207824A2 (en) * 2015-06-23 2016-12-29 Dr. Reddy's Laboratories Ltd A stable pharmaceutical composition comprising ramipril and/or amlodipine
EP3501502A1 (en) * 2017-12-20 2019-06-26 Midas Pharma GmbH Fixed dosed pharmaceutical compositions comprising amlodipine, ramipril and atorvastatin

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3633496A1 (de) 1986-10-02 1988-04-14 Hoechst Ag Kombination von angiotensin-converting-enzyme-hemmern mit calciumantagonisten sowie deren verwendung in arzneimitteln
PT804229E (pt) 1995-03-16 2003-06-30 Pfizer Utilizacao de amlodipina de um dos seus sais ou defelodipina em combinacao com um inibidor da en zima de conversao da angiotensina (ace) para no fabrico de um medicamento destinado ao tratamento da insuficiencia cardiaca congestiva nao isquemica
CA2382549C (en) 1999-08-30 2005-03-15 Aventis Pharma Deutschland Gmbh Use of inhibitors of the renin-angiotensin system in the prevention of cardiovascular events
WO2005079772A2 (en) 2004-02-18 2005-09-01 Sepracor Inc. Combination of (s)-amlodipine and an ace inhibitor, and methods for reducing hypertension
HUP0401170A2 (en) * 2004-06-10 2006-09-28 Richter Gedeon Vegyeszet Pharmaceutical composition comprising amlodipine besilate and lisinopril dihydrate and process for
CN101098679A (zh) * 2004-11-05 2008-01-02 国王医药研究与发展有限公司 稳定的雷米普利组合物及其制备方法
AU2005336956A1 (en) * 2005-09-28 2007-04-12 Teva Pharmaceutical Industries Ltd. Stable combinations of amlodipine besylate and benazepril hydrochloride
CN101272791A (zh) * 2005-09-28 2008-09-24 特瓦制药工业有限公司 苯磺酸氨氯地平和盐酸贝那普利的稳定的组合
TWI399223B (zh) * 2006-09-15 2013-06-21 Daiichi Sankyo Co Ltd 奧美沙坦酯及氨氯地平之固體劑型
US20080096863A1 (en) * 2006-10-19 2008-04-24 Torrent Pharmaceuticals Limited Stable pharmaceutical compositions of calcium channel blocker and an ACE inhibitor

Also Published As

Publication number Publication date
MX2012009689A (es) 2012-09-12
PL2538924T3 (pl) 2014-10-31
WO2011104588A3 (en) 2012-04-19
CR20120432A (es) 2012-11-29
UA105285C2 (uk) 2014-04-25
KR20120130761A (ko) 2012-12-03
ES2483154T3 (es) 2014-08-05
BR112012021203A2 (pt) 2016-05-17
SG183449A1 (en) 2012-09-27
JP2013520485A (ja) 2013-06-06
UY33243A (es) 2011-09-30
EP2538924A2 (en) 2013-01-02
TW201138767A (en) 2011-11-16
CN102781430A (zh) 2012-11-14
CA2790817A1 (en) 2011-09-01
ZA201205559B (en) 2013-09-25
EA201290817A1 (ru) 2013-01-30
MA34130B1 (fr) 2013-04-03
PE20130004A1 (es) 2013-02-01
WO2011104588A2 (en) 2011-09-01
NI201200136A (es) 2012-10-29
TN2012000363A1 (en) 2014-01-30
GT201200248A (es) 2014-05-14
AU2010346977A1 (en) 2012-09-13
JP5719385B2 (ja) 2015-05-20
SI2538924T1 (sl) 2014-09-30
CN102781430B (zh) 2015-09-09
ECSP12012121A (es) 2012-09-28
US20130146496A1 (en) 2013-06-13
CL2012002341A1 (es) 2012-11-30
EP2538924B1 (en) 2014-05-21

Similar Documents

Publication Publication Date Title
AR077284A1 (es) Composiciones de dosis fija farmaceuticas solidas que comprenden irbesartan y amlodipina, su preparacion y su aplicacion terapeutica
EA201400172A1 (ru) Устойчивая к разрушению таблетка, которая обеспечивает немедленное высвобождение лекарственного средства
CL2008003298A1 (es) Forma de dosificacion oral solida que comprende a) un compuesto de accion doble en concentracion entre 4 y 90%, b) un excipiente farmaceuticamente aceptable; proceso de preparación; uso en el tratamiento de enfermedades cardiovasculares y/o renales.
UA116334C2 (uk) Тверді форми дозування бендамустину
AR080256A1 (es) Formulaciones farmaceuticas solidas de ramipril y besilato de amlodipino y su preparacion
MX340188B (es) Elaboracion de granulos sin activos y tabletas que comprenden los mismos.
TN2015000135A1 (en) Modified release formulations for oprozomib
EA201690679A1 (ru) Стабильная фармацевтическая композиция, содержащая амлодипин и валсартан
PE20131035A1 (es) Formulacion de nevirapina de liberacion prolongada
CL2013003176A1 (es) Formulacion farmaceutica oral de liberacion sostenida que comprende dos tabletas que contienen 1000 mg de paracetamol, el cual esta presente en una capa de liberacion sostenida y otra de liberacion inmediata, en una proporcion de paracetamol por capa de 80-90 %: 10-20 %, donde la dosis unitaria comprende 2000 mg de paracetamol.
PE20160245A1 (es) Composicion farmaceutica anti-tuberculosis estable en una forma de un comprimido dispersable que comprende granulos de isoniazid y granulos de rifapentina y su proceso de preparacion
CL2022000095A1 (es) Composiciones farmacéuticas resistentes a la descarga de dosis que comprenden venirunad
ECSP16005208A (es) Composición farmacéutica anti-tuberculosis estable en una forma de un comprimido recubierto que comprende gránulos de isoniazid y gránulos de rifapentina y su proceso de preparación
PE20200174A1 (es) Composiciones farmaceuticas
AR109693A1 (es) Formulaciones de liberación inmediata de oprozomib
CO6721021A2 (es) Comprimido farmacéutico de liberación controlada para dministración oral
AR077244A1 (es) Composicion farmaceutica que comprende poli (alilamin-co-n,n'-dialil-1,3-diamino-2-hidroxipropano )
JP2017514820A5 (es)
UA105513C2 (uk) Лікарська форма уповільненого вивільнення глюкозаміну
CU20130165A7 (es) Liberación modificada de 4-metil-3-[[-4-(3- piridinil)-2-pirimidinil]amino]-n-5-(4- metil-1h-imidazol-1- il)-3- (trifluorometil) fenil] benzamida solubilizada utilizando acidos orgánicos
UA110792C2 (uk) Лікарська форма бендамустину для перорального застосування
RU2012133273A (ru) Сублингвальная форма 6-метил-2-этил-3-гидроксипиридина и ее применение в качестве средства, обладающего стимулирующей, анорексигенной, антидепрессивной, анксиолитической, противогипоксической, антиамнестической (ноотропной) и антиалкогольной активностью

Legal Events

Date Code Title Description
FB Suspension of granting procedure